title: Hormone therapy in combination with radiotherapy in the treatment of prostate cancer: why and in which group of patients?
abstract: In recent years, significant development in the treatment of prostate cancer has taken place. One of the most documented methods of treatment in patients characterised by a high risk of progression is a combination of radiotherapy (RT) with long-term hormone therapy (HT). In this group of patients, neither RT alone nor HT alone allows satisfactory outcomes to be achieved, and therefore as monotherapy they are not recommended as optimal methods of treatment. In this review, we summarise arguments for combining radiotherapy with hormonal therapy in high-risk prostate cancer, with an emphasis on the results of phase III trials.
authors.affiliation: Department and Clinic of Urology and Urologic Oncology, Poznan University of Medical Science, Poznan, Poland.
authors.forename: Tomasz
authors.initials: T
authors.lastname: Milecki
authors.affiliation: Department and Clinic of Urology and Urologic Oncology, Poznan University of Medical Science, Poznan, Poland.
authors.forename: Andrzej
authors.initials: A
authors.lastname: Antczak
authors.affiliation: Department and Clinic of Urology and Urologic Oncology, Poznan University of Medical Science, Poznan, Poland.
authors.forename: Zbigniew
authors.initials: Z
authors.lastname: Kwias
authors.affiliation: Chair and Department of Electroradiology, Poznan University of Medical Sciences, Poznan, Poland ; Department of Radiotherapy, Greater Poland Cancer Centre, Poznan, Poland.
authors.forename: Piotr
authors.initials: P
authors.lastname: Milecki
keywords: combination therapy; hormone therapy; prostate cancer; radiotherapy